– UK, London – IXICO plc (Ticker: IXI), the brain health company, announces that Susan Lowther FCMA has been appointed to the board as Chief Financial Officer with effect from 1 October 2014.

Susan (aged 54) was previously Group Chief Financial Officer and a director of Novacyt SA, a European company listed on the French Alternext exchange. Novacyt specialises in cancer and infectious disease diagnostic products and services, operating from four sites in France and the UK. 

Prior to this she was Chief Financial Officer and a director of Lab21 Group Limited, which was acquired by Novacyt in June 2014 by way of a share for share transaction valuing the enlarged group at c.€40 million.  Susan was previously Chief Executive Officer at BioWisdom Limited and has held finance roles in life science companies including RiboTargets, Lonza Biologics, Celltech Group and Monsanto.

Commenting on the appointment Derek Hill, CEO of IXICO, said: “We are delighted that Susan is joining the IXICO team.  She brings a depth of financial and business experience that will help us continue to grow the business internationally.”

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.